FEMYHIGH SIGNALFINANCIAL10-K

FEMY completed significant equity financing that substantially improved its balance sheet position while reducing current liabilities and expanding inventory investment.

The company's outstanding shares more than doubled from 27.1M to 60.4M shares, indicating a major equity raise that provided capital to fund operations and product development. The substantial reduction in current liabilities from $8.6M to $3.6M suggests the company addressed near-term financial pressures, while the meaningful inventory build indicates preparation for increased commercial activity.

Comparing 2026-03-31 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

FEMY's financial position improved markedly through what appears to be a substantial equity financing, with total assets growing from $12.4M to $20.7M while current liabilities fell meaningfully. Revenue grew modestly to $2.3M, and the company invested in expanding inventory levels to $5.7M. The dilutive equity raise appears to have provided the capital needed to strengthen the balance sheet and support the company's transition from development to commercialization phase.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
+88.4%
$3.0M$5.7M

Inventory surged 88.4% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Share Buybacks
Cash Flow
-73.6%
$230K$61K

Buyback activity reduced 73.6% — capital being redeployed elsewhere or cash conservation underway.

Total Assets
Balance Sheet
+66.5%
$12.4M$20.7M

Asset base grew 66.5% — expansion through organic growth, acquisitions, or capital deployment.

Current Liabilities
Balance Sheet
-57.6%
$8.6M$3.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
+46.5%
$10.1M$14.9M

Liabilities grew 46.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
+40.8%
$1.6M$2.3M

Strong top-line growth of 40.8% — accelerating demand or successful expansion into new markets.

Capital Expenditure
Cash Flow
-31.1%
$762K$525K

Capex reduced 31.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
+26.3%
$488K$617K

Receivables grew 26.3% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-27
ADDED
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.
As of March 30, 2026, there were 60,390,686 shares of the registrant s $0.001 par value common stock outstanding.
These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to, statements concerning: our ability to obtain additional financing to fund commercialization of our products and fund our operations; our ability to obtain additional financing to fund the U.S.
product candidate FemBloc permanent birth control; our ability to obtain U.S.
+7 more — sign up free →
REMOVED
As of March 26, 2025, there were 27,149,971 shares of the registrant s $0.001 par value common stock outstanding.
Forward-looking statements include, but are not limited to, statements concerning: our ability to obtain additional financing to fund the clinical development and commercialization of our product candidate FemBloc permanent birth control, if approved for sale, approved products and fund our operations; our ability to pay our convertible notes due November 2025 when due, if not converted into common stock; our ability to obtain U.S.
or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals or clearances; our ability to establish and maintain intellectual property protection for our products and product candidate and our ability to avoid claims of infringement; and the volatility of the trading price of our common stock.
The FDA may not allow us to continue the ongoing pivotal trial for FemBloc Premarket approval (PMA) due to safety concerns.
We are substantially dependent on the FDA s permission to market our FemBloc system.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →